InvestorsHub Logo
Post# of 252301
Next 10
Followers 0
Posts 75
Boards Moderated 0
Alias Born 03/22/2004

Re: biomaven0 post# 128357

Thursday, 10/13/2011 3:55:02 PM

Thursday, October 13, 2011 3:55:02 PM

Post# of 252301
Here is what LS had to say as posted on yahoo
Leerink Swann reiterates an 'Outperform' on Incyte (NASDAQ: INCY), low/mid-$20's target valuation.

Leerink analyst says, "We believe INCY shares are trading down in response to an NEJM article by Dr. Ayalew Tefferi from the Mayo Clinic. The article discusses 51 patients with myelofibrosis treated with Ruxolitinib and notes a high drop-off rate and inconsistent durable effects. While on the surface this would appear to be problematic for Ruxolitinib's prospects, we note material omissions in the publication and are actually surprised the NEJM would publish such analysis as, in our view, it is deficient. We believe the analysis mischaracterizes Ruxolitinib's profile."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.